Magnesium Sulfate Injection Rx
Generic Name and Formulations:
Magnesium sulfate 500mg/mL; soln for IM inj; or IV use after dilution; contains aluminum.
Various generic manufacturers
Indications for Magnesium Sulfate Injection:
Mild deficiency: 1g IM every 6 hours for four doses. Severe deficiency: 250mg/kg IM within a period of 4 hours if necessary; alternatively 5g may be added to one liter of 5% dextrose inj or 0.9% sodium chloride inj for slow IV infusion over a 3-hour period. TPN: usual range: 1–3g (8–24mEq) daily. Severe renal impairment: max 20g in 48 hours.
TPN for infants: usual range: 0.25–1.25g (2–10mEq) daily.
Heart block. Myocardial damage.
Renal impairment. Monitor serum magnesium levels; if repeated doses are given, test knee jerk reflexes before each dose. Have injectable calcium salt readily available to counteract magnesium intoxication. Elderly. Premature neonates. Pregnancy (Cat.D). Nursing mothers.
Additive CNS depressant effects with barbiturates, narcotics, other hypnotics; adjust dose. Potentiates neuromuscular blocking agents. Concomitant cardiac glycosides; use extreme caution, heart block may occur.
Magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis.
Formerly known under the brand name Sulfamag.
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Does Maintenance of Certification Status Affect Patient Care?
- Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder
- Reduced Mortality for Women Undergoing Assisted Reproduction Likely Due to "Healthy Patient Effect"
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women